The Safety of Melatonin in Humans

Lars Peter Holst Andersen, Ismail Gögenur, Jacob Rosenberg, Russel J Reiter

Research output: Contribution to journalReview article

65 Citations (Scopus)

Abstract

Exogenous melatonin has been investigated as treatment for a number of medical and surgical diseases, demonstrating encouraging results. The aim of this review was to present and evaluate the literature concerning the possible adverse effects and safety of exogenous melatonin in humans. Furthermore, we provide recommendations concerning the possible risks of melatonin use in specific patient groups. In general, animal and human studies documented that short-term use of melatonin is safe, even in extreme doses. Only mild adverse effects, such as dizziness, headache, nausea and sleepiness have been reported. No studies have indicated that exogenous melatonin should induce any serious adverse effects. Similarly, randomized clinical studies indicate that long-term melatonin treatment causes only mild adverse effects comparable to placebo. Long-term safety of melatonin in children and adolescents, however, requires further investigation. Due to a lack of human studies, pregnant and breast-feeding women should not take exogenous melatonin at this moment.

Original languageEnglish (US)
Pages (from-to)169-175
Number of pages7
JournalClinical Drug Investigation
Volume36
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Melatonin
Safety
Dizziness
Breast Feeding
Nausea
Headache
Placebos
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

The Safety of Melatonin in Humans. / Andersen, Lars Peter Holst; Gögenur, Ismail; Rosenberg, Jacob; Reiter, Russel J.

In: Clinical Drug Investigation, Vol. 36, No. 3, 01.03.2016, p. 169-175.

Research output: Contribution to journalReview article

Andersen, LPH, Gögenur, I, Rosenberg, J & Reiter, RJ 2016, 'The Safety of Melatonin in Humans', Clinical Drug Investigation, vol. 36, no. 3, pp. 169-175. https://doi.org/10.1007/s40261-015-0368-5
Andersen, Lars Peter Holst ; Gögenur, Ismail ; Rosenberg, Jacob ; Reiter, Russel J. / The Safety of Melatonin in Humans. In: Clinical Drug Investigation. 2016 ; Vol. 36, No. 3. pp. 169-175.
@article{34c774ba22754e359472b2af19cdba74,
title = "The Safety of Melatonin in Humans",
abstract = "Exogenous melatonin has been investigated as treatment for a number of medical and surgical diseases, demonstrating encouraging results. The aim of this review was to present and evaluate the literature concerning the possible adverse effects and safety of exogenous melatonin in humans. Furthermore, we provide recommendations concerning the possible risks of melatonin use in specific patient groups. In general, animal and human studies documented that short-term use of melatonin is safe, even in extreme doses. Only mild adverse effects, such as dizziness, headache, nausea and sleepiness have been reported. No studies have indicated that exogenous melatonin should induce any serious adverse effects. Similarly, randomized clinical studies indicate that long-term melatonin treatment causes only mild adverse effects comparable to placebo. Long-term safety of melatonin in children and adolescents, however, requires further investigation. Due to a lack of human studies, pregnant and breast-feeding women should not take exogenous melatonin at this moment.",
author = "Andersen, {Lars Peter Holst} and Ismail G{\"o}genur and Jacob Rosenberg and Reiter, {Russel J}",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s40261-015-0368-5",
language = "English (US)",
volume = "36",
pages = "169--175",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - The Safety of Melatonin in Humans

AU - Andersen, Lars Peter Holst

AU - Gögenur, Ismail

AU - Rosenberg, Jacob

AU - Reiter, Russel J

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Exogenous melatonin has been investigated as treatment for a number of medical and surgical diseases, demonstrating encouraging results. The aim of this review was to present and evaluate the literature concerning the possible adverse effects and safety of exogenous melatonin in humans. Furthermore, we provide recommendations concerning the possible risks of melatonin use in specific patient groups. In general, animal and human studies documented that short-term use of melatonin is safe, even in extreme doses. Only mild adverse effects, such as dizziness, headache, nausea and sleepiness have been reported. No studies have indicated that exogenous melatonin should induce any serious adverse effects. Similarly, randomized clinical studies indicate that long-term melatonin treatment causes only mild adverse effects comparable to placebo. Long-term safety of melatonin in children and adolescents, however, requires further investigation. Due to a lack of human studies, pregnant and breast-feeding women should not take exogenous melatonin at this moment.

AB - Exogenous melatonin has been investigated as treatment for a number of medical and surgical diseases, demonstrating encouraging results. The aim of this review was to present and evaluate the literature concerning the possible adverse effects and safety of exogenous melatonin in humans. Furthermore, we provide recommendations concerning the possible risks of melatonin use in specific patient groups. In general, animal and human studies documented that short-term use of melatonin is safe, even in extreme doses. Only mild adverse effects, such as dizziness, headache, nausea and sleepiness have been reported. No studies have indicated that exogenous melatonin should induce any serious adverse effects. Similarly, randomized clinical studies indicate that long-term melatonin treatment causes only mild adverse effects comparable to placebo. Long-term safety of melatonin in children and adolescents, however, requires further investigation. Due to a lack of human studies, pregnant and breast-feeding women should not take exogenous melatonin at this moment.

UR - http://www.scopus.com/inward/record.url?scp=84975759978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975759978&partnerID=8YFLogxK

U2 - 10.1007/s40261-015-0368-5

DO - 10.1007/s40261-015-0368-5

M3 - Review article

VL - 36

SP - 169

EP - 175

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 3

ER -